Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven D Nathan

Showing results (261-270 of 297) with videos related to

Pageof 30
Sort By:
BMJ Open Respiratory Research|February 3, 2016
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trialsLisa Lancaster, Carlo Albera, Williamson Z Bradford, et al.
The European Respiratory Journal|December 10, 2015
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trialsPaul W Noble, Carlo Albera, Williamson Z Bradford, et al.
Pulmonary Circulation|August 26, 2022
Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertensionSylvia M Nikkho, Manuel J Richter, Eric Shen, et al.
The European Respiratory Journal|March 7, 2020
Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registryOksana A Shlobin, Vasilis Kouranos, Scott D Barnett, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|February 4, 2022
Echocardiographic estimate of pulmonary artery pressure in sarcoidosis patients - real world data from a multi-national studyMarloes P Huitema, Marco C Post, Jan C Grutters, et al.
Respiratory Medicine|March 22, 2022
The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registryRohit Gupta, Robert P Baughman, Steven D Nathan, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 1, 2022
Clinical features and allograft failure rates of pulmonary antibody-mediated rejection categoriesAnanth V Charya, Ileana L Ponor, Adam Cochrane, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|March 21, 2021
Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP studySteven D Nathan, Vincent Cottin, Juergen Behr, et al.
Annals of the American Thoracic Society|August 11, 2020
The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and MethodsBonnie R Wang, Rex Edwards, Elizabeth A Freiheit, et al.
American Journal of Respiratory and Critical Care Medicine|December 20, 2023
Cell-Free DNA Maps Tissue Injury and Correlates with Disease Severity in Lung Transplant CandidatesShanti Balasubramanian, Mary E Richert, Hyesik Kong, et al.
Pageof 30

Showing results (261-270 of 297) with videos related to

Sort By:
Pageof 30
BMJ Open Respiratory Research|February 3, 2016
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trialsLisa Lancaster, Carlo Albera, Williamson Z Bradford, et al.
The European Respiratory Journal|December 10, 2015
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trialsPaul W Noble, Carlo Albera, Williamson Z Bradford, et al.
Pulmonary Circulation|August 26, 2022
Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertensionSylvia M Nikkho, Manuel J Richter, Eric Shen, et al.
The European Respiratory Journal|March 7, 2020
Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registryOksana A Shlobin, Vasilis Kouranos, Scott D Barnett, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|February 4, 2022
Echocardiographic estimate of pulmonary artery pressure in sarcoidosis patients - real world data from a multi-national studyMarloes P Huitema, Marco C Post, Jan C Grutters, et al.
Respiratory Medicine|March 22, 2022
The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registryRohit Gupta, Robert P Baughman, Steven D Nathan, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 1, 2022
Clinical features and allograft failure rates of pulmonary antibody-mediated rejection categoriesAnanth V Charya, Ileana L Ponor, Adam Cochrane, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|March 21, 2021
Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP studySteven D Nathan, Vincent Cottin, Juergen Behr, et al.
Annals of the American Thoracic Society|August 11, 2020
The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and MethodsBonnie R Wang, Rex Edwards, Elizabeth A Freiheit, et al.
American Journal of Respiratory and Critical Care Medicine|December 20, 2023
Cell-Free DNA Maps Tissue Injury and Correlates with Disease Severity in Lung Transplant CandidatesShanti Balasubramanian, Mary E Richert, Hyesik Kong, et al.
Pageof 30